{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:13:08Z","timestamp":1772493188367,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T00:00:00Z","timestamp":1289433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s10549-010-1248-6","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T01:24:34Z","timestamp":1289352274000},"page":"421-432","source":"Crossref","is-referenced-by-count":41,"title":["Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features"],"prefix":"10.1007","volume":"129","author":[{"given":"Gulnur","family":"Guler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Himmetoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael E.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenle P.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Costinean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Pilarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinc","family":"Suren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,11]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1073\/pnas.0708097105","volume":"105","author":"SG Durkin","year":"2008","unstructured":"Durkin SG, Ragland RL, Arlt MF, Mulle JG, Warren ST, Glover TW (2008) Replication stress induces tumor-like microdeletions in FHIT\/FRA3B. Proc Natl Acad Sci USA 105:246\u2013251","journal-title":"Proc Natl Acad Sci USA"},{"key":"1248_CR2","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/sj.onc.1210989","volume":"27","author":"PK Tsantoulis","year":"2008","unstructured":"Tsantoulis PK, Kotsinas A, Sfikakis PP, Evangelou K, Sideridou M, Levy B, Mo L, Kittas C, Wu XR, Papavassiliou AG, Gorgoulis VG (2008) Oncogene induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene 27:3256\u20133264","journal-title":"Oncogene"},{"key":"1248_CR3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.20137","volume":"100","author":"G Guler","year":"2004","unstructured":"Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, McCue P, Huebner K (2004) The fragile genes, FHIT and WWOX, are coordinately inactivated in invasive breast cancer: correlations with clinical features. Cancer 100:1605\u20131614","journal-title":"Cancer"},{"key":"1248_CR4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.24103","volume":"115","author":"G Guler","year":"2009","unstructured":"Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, Hayran M, Shapiro C (2009) Fragile histidine triad protein, WW domain-containing oxidoreductase protein, and activator protein 2 gamma expression levels correlate with basal phenotype in breast cancer. Cancer 115:899\u2013908","journal-title":"Cancer"},{"key":"1248_CR5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1440-1827.2005.01855.x","volume":"55","author":"G Guler","year":"2005","unstructured":"Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, Huebner K (2005) Concordant loss of fragile genes, Fhit and Wwox, in breast cancer development. Pathol Int 55:471\u2013478","journal-title":"Pathol Int"},{"key":"1248_CR6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nature03485","volume":"434","author":"VG Gorgoulis","year":"2005","unstructured":"Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907\u2013913","journal-title":"Nature"},{"key":"1248_CR7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","volume":"434","author":"J Bartkova","year":"2005","unstructured":"Bartkova J, Horejsi Z, Koed K, Kr\u00e4mer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, \u00d8rntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864\u2013870","journal-title":"Nature"},{"key":"1248_CR8","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","volume":"26","author":"J Bartek","year":"2007","unstructured":"Bartek J, Bartkova J, Lukas J (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26:7773\u20137779","journal-title":"Oncogene"},{"key":"1248_CR9","first-page":"5032","volume":"58","author":"G Sozzi","year":"1998","unstructured":"Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S (1998) Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58:5032\u20135037","journal-title":"Cancer Res"},{"key":"1248_CR10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2217\/14796694.4.6.815","volume":"4","author":"F Pichiorri","year":"2008","unstructured":"Pichiorri F, Palumbo T, Suh S-S, Okumura H, Trapasso F, Ishii H, Huebner K, Croce CM (2008) The Fhit tumor suppressor: \u2018guardian of the preneoplastic genome\u2019. Future Oncol 4:815\u2013824","journal-title":"Future Oncol"},{"key":"1248_CR11","first-page":"249","volume":"6","author":"R Cirombella","year":"2010","unstructured":"Cirombella R, Montrone G, Stoppacciaro A, Giglio S, Volinia S, Graziano P, Huebner K, Vecchione A (2010) Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. Cancer Lett 6:249\u2013259","journal-title":"Cancer Lett"},{"key":"1248_CR12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.4161\/cc.6.9.4213","volume":"6","author":"H Ishii","year":"2007","unstructured":"Ishii H, Wang Y, Huebner K (2007) A Fhit-ing role in the DNA damage checkpoint response. Cell Cycle 6:1044\u20131048","journal-title":"Cell Cycle"},{"key":"1248_CR13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe R, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917\u2013921","journal-title":"Nature"},{"key":"1248_CR14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913\u2013917","journal-title":"Nature"},{"key":"1248_CR15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr2566","volume":"12","author":"BP Rowe","year":"2010","unstructured":"Rowe BP, Glazer PM (2010) Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 12:203\u2013214","journal-title":"Breast Cancer Res"},{"key":"1248_CR16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e31818d839b","volume":"14","author":"AR Tan","year":"2008","unstructured":"Tan AR, Swain SM (2008) Therapeutic strategies for triple-negative breast cancer. Cancer J 14:343\u2013351","journal-title":"Cancer J"},{"key":"1248_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O\u2019Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123\u2013134","journal-title":"N Engl J Med"},{"key":"1248_CR18","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/0008-5472.CAN-08-4016","volume":"69","author":"E Alli","year":"2009","unstructured":"Alli E, Sharma VB, Sunderesakumar P, Ford JM (2009) Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 69:3589\u20133596","journal-title":"Cancer Res"},{"key":"1248_CR19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A (2004) Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer 4:814\u2013819","journal-title":"Nat Rev Cancer"},{"key":"1248_CR20","first-page":"2682","volume":"59","author":"S Ingvarsson","year":"1999","unstructured":"Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, Kononen J, Kallioniemi OP, Barkardottir RB, Kovatich AJ, Schwarting R, Hauck WW, Huebner K, McCue PA (1999) Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res 59:2682\u20132689","journal-title":"Cancer Res"},{"key":"1248_CR21","first-page":"4054","volume":"62","author":"BC Turner","year":"2002","unstructured":"Turner BC, Ottey M, Zimonjic DB, Potoczek M, Hauck WW, Pequignot E, Keck-Waggoner CL, Sevignani C, Aldaz CM, McCue PA, Palazzo J, Huebner K, Popescu NC (2002) The fragile histidine triad\/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res 62:4054\u20134060","journal-title":"Cancer Res"},{"key":"1248_CR22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cancergencyto.2010.01.019","volume":"199","author":"EW Silva Soares","year":"2010","unstructured":"Silva Soares EW, de Lima Santos SC, Bueno AG, Cavalli IJ, Cavalli LR, Fouto Matias JE, de Souza Fonseca Ribeiro EM (2010) Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer. Cancer Genet Cytogenet 199:24\u201330","journal-title":"Cancer Genet Cytogenet"},{"key":"1248_CR23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcb.20355","volume":"94","author":"L Li","year":"2005","unstructured":"Li L, Zou L (2005) Sensing, signaling, and responding to DNA damage: organization of the checkpoint pathways in mammalian cells. J Cell Biochem 94:298\u2013306","journal-title":"J Cell Biochem"},{"key":"1248_CR24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"MB Kastan","year":"2004","unstructured":"Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432:316\u2013323","journal-title":"Nature"},{"key":"1248_CR25","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.dnarep.2006.05.010","volume":"5","author":"MF Arlt","year":"2006","unstructured":"Arlt MF, Durkin SG, Ragland RL, Glover TW (2006) Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst) 5:1126\u20131135","journal-title":"DNA Repair (Amst)"},{"key":"1248_CR26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1139\/o06-072","volume":"84","author":"J Fillingham","year":"2006","unstructured":"Fillingham J, Keogh MC, Krogan NJ (2006) GammaH2AX and its role in DNA double-strand break repair. Biochem Cell Biol 84:568\u2013577","journal-title":"Biochem Cell Biol"},{"key":"1248_CR27","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/nar\/gkl010","volume":"34","author":"CX Deng","year":"2006","unstructured":"Deng CX (2006) BRCA1: ccll cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34:1416\u20131426","journal-title":"Nucleic Acids Res"},{"key":"1248_CR28","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T S\u00f8rlie","year":"2001","unstructured":"S\u00f8rlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein L\u00f8nning P, B\u00f8rresen-Dale A (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869\u201310874","journal-title":"Proc Natl Acad Sci USA"},{"key":"1248_CR29","first-page":"141","volume":"12","author":"JC Niland","year":"1998","unstructured":"Niland JC (1998) NCCN Internet-based data system for the conduct of outcomes research. Oncology 12:141\u2013146","journal-title":"Oncology"},{"key":"1248_CR30","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1158\/1078-0432.CCR-07-1282","volume":"13","author":"G Guler","year":"2007","unstructured":"Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K (2007) Wwox and Ap2\u03b3 expression levels predict tamoxifen response. Clin Cancer Res 13:6115\u20136121","journal-title":"Clin Cancer Res"},{"key":"1248_CR31","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","volume":"10","author":"TO Nielson","year":"2004","unstructured":"Nielson TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367\u20135374","journal-title":"Clin Cancer Res"},{"key":"1248_CR32","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","volume":"14","author":"MC Cheang","year":"2008","unstructured":"Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368\u20131376","journal-title":"Clin Cancer Res"},{"key":"1248_CR33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/1267601","volume":"16","author":"GM Furnival","year":"1974","unstructured":"Furnival GM, Wilson RW Jr (1974) Regressions by leaps and bounds. Technometrics 16:499\u2013511","journal-title":"Technometrics"},{"key":"1248_CR34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm.2000","volume":"8","author":"E Lim","year":"2009","unstructured":"Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, ConFab k, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 8:907\u2013913","journal-title":"Nat Med"},{"key":"1248_CR35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/nrc1212","volume":"3","author":"M Smalley","year":"2003","unstructured":"Smalley M, Ashworth A (2003) Stem cells and breast cancer: a field in transit. Nat Rev Cancer 3:832\u2013844","journal-title":"Nat Rev Cancer"},{"key":"1248_CR36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tem.2004.05.011","volume":"15","author":"G Dontu","year":"2004","unstructured":"Dontu G, El-Ashry D, Wicha MS (2004) Breast cancer, stem\/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15:193\u2013197","journal-title":"Trends Endocrinol Metab"},{"key":"1248_CR37","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1073\/pnas.0711613105","volume":"105","author":"S Liu","year":"2008","unstructured":"Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS (2008) BRCA1 regulates human mammary stem\/progenitor cell fate. Proc Natl Acad Sci USA 105:1680\u20131685","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"1248_CR38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-8049(09)70012-7","volume":"45","author":"SC Linn","year":"2009","unstructured":"Linn SC, Van \u2018t Veer LJ (2009) Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 45(Suppl 1):11\u201326","journal-title":"Eur J Cancer"},{"key":"1248_CR39","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1158\/0008-5472.CAN-07-5687","volume":"68","author":"H Ishii","year":"2008","unstructured":"Ishii H, Mimori K, Ishikawa K, Okumura H, Pichiorri F, Druck T, Inoue H, Vecchione A, Saito T, Mori M, Huebner K (2008) Fhit-deficient hematopoietic stem cells survive hydroquinone exposure carrying precancerous changes. Cancer Res 68:3662\u20133670","journal-title":"Cancer Res"},{"key":"1248_CR40","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/bcr2486","volume":"12","author":"H Asakawa","year":"2010","unstructured":"Asakawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H, Fukuda M, Ohta T (2010) Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 12:R17","journal-title":"Breast Cancer Res"},{"key":"1248_CR41","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-08-2974","volume":"69","author":"C Gourley","year":"2009","unstructured":"Gourley C, Paige AJ, Taylor KJ, Ward C, Kuske B, Zhang J, Sun M, Janczar S, Harrison DJ, Muir M, Smyth JF, Gabra H (2009) WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res 69:4835\u20134842","journal-title":"Cancer Res"},{"key":"1248_CR42","first-page":"529","volume":"44","author":"JQ Zhang","year":"2009","unstructured":"Zhang JQ, Li L, Song HL, Paige A, Gabra H (2009) Effects of WWOX on ovarian cancer cell attachment in vitro. Zhonghua Fu Chan Ke Za Zhi 44:529\u2013532","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"1248_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10911-008-9079-3","volume":"13","author":"M Sundvall","year":"2008","unstructured":"Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K (2008) Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 13:259\u2013268","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"1248_CR44","doi-asserted-by":"crossref","unstructured":"Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ (2010) Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes Cancer 49:948\u2013962","DOI":"10.1002\/gcc.20807"},{"key":"1248_CR45","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.2353\/ajpath.2009.090204","volume":"175","author":"AD Thor","year":"2009","unstructured":"Thor AD, Edgerton SM, Jones FE (2009) Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol 175:1802\u20131809","journal-title":"Am J Pathol"},{"key":"1248_CR46","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-07-2147","volume":"67","author":"RI Aqeilan","year":"2007","unstructured":"Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H, Croce CM, Elenius K (2007) Association of Wwox with ErbB4 in breast cancer. Cancer Res 67:9330\u20139336","journal-title":"Cancer Res"},{"key":"1248_CR47","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1210\/me.2006-0101","volume":"21","author":"SM Feng","year":"2007","unstructured":"Feng SM, Sartor CI, Hunter D, Zhou H, Yang X, Caskey LS, Dy R, Muraoka-Cook RS, Earp HS 3rd (2007) The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol Endocrinol 21:1861\u20131876","journal-title":"Mol Endocrinol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1248-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1248-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T01:05:07Z","timestamp":1559783107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1248-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,11]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1248-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,11]]}}}